SCHEMBL19259508

SCHEMBL19259508

O=c1cc(O)cc(-c2ccccc2Cl)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 4/20 0.52
GPR84 Q9NQS5 4/20 0.49
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
ALOX15 P16050 2/20 0.45
HSD17B10 Q99714 2/20 0.45
POLB P06746 2/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PIM1 P11309 2/20 0.45
HTT P42858 1/20 0.44
TNKS2 Q9H2K2 1/20 0.43
MEN1 O00255 3/20 0.43
HPGD P15428 3/20 0.43
KMT2A Q03164 3/20 0.43
ALOX12 P18054 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19259409 0.84 PIK3C3 (0.56) PIK3C3ALDH1A1MAPTALOX15HSD17B10
SCHEMBL2448447 0.81 GPR84 (0.46) GPR84MAPTL3MBTL1HTTMEN1
SCHEMBL26503024 0.79 PIK3C3 (0.52) PIK3C3ALDH1A1MAPTALOX15HSD17B10
SCHEMBL3757426 0.79 PIK3C3 (0.51) PIK3C3GPR84ALDH1A1MAPTALOX15
SCHEMBL8987394 0.78 PIK3C3 (0.64) PIK3C3ALDH1A1MAPTALOX15HSD17B10
SCHEMBL20764775 0.76 PIK3C3 (0.49) PIK3C3GPR84ALDH1A1MEN1HPGD
SCHEMBL3329851 0.74 PIM1 (0.65) PIK3C3ALDH1A1MAPTALOX15HSD17B10
SCHEMBL30602735 0.74 NOTUM (0.53) PIK3C3ALDH1A1MAPTALOX15HSD17B10
SCHEMBL8987087 0.71 PIK3C3 (0.53) PIK3C3GPR84ALDH1A1MAPTALOX15
SCHEMBL9377820 0.70 ESR1 (0.44) PIK3C3ALDH1A1MAPTALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Spring Bioscience AB (SE) 2024-02-15 US disclosed
CN-116903526-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-20 CN disclosed
CN-116891431-A Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-10-17 CN disclosed
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2023-10-12 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds SPRINT BIOSCIENCE AB (SE) 2023-10-10 US disclosed
CN-116589461-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
CN-116589462-A Azaindolylpyridone compounds and diazaindolylpyridone compounds 思普瑞特生物科学公司 2023-08-15 CN disclosed
CN-111094244-B Pyridinylpyridinone compounds 思普瑞特生物科学公司 2023-07-11 CN disclosed
CN-111094244-A Pyridylpyridone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
CN-111094271-A Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2020-05-01 CN disclosed
WO-2019038389-A1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038384-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038384-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
WO-2019038387-A1 PYRIDYLPYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2019-02-28 WO disclosed
EP-3416945-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES Sprint Bioscience AB (SE) 2018-12-26 EP disclosed
WO-2017140841-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2017-08-24 WO disclosed
WO-2017140841-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES SPRINT BIOSCIENCE AB (SE) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322772-A1 AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS AZI2, IAPP, ZFX PIK3C3 1407/4885GPR84 3708/4885ALDH1A1 1426/4885
US-11780858-B2 Pyridinamine-pyridone and pyrimidinamine-pyridone compounds PDXK, PLPBP, PNPO PIK3C3 3787/4885GPR84 1616/4885ALDH1A1 1779/4885
US-20240050439-A1 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES PYCR1, GPR119, CDK6 PIK3C3 4489/4885GPR84 2021/4885ALDH1A1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.